New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
07:14 EDTMNK, DEPOFDA PDUFA Date for Depomed/Mallinckrodt MNK-795 is January 29, 2014
News For DEPO;MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
06:56 EDTMNKMallinckrodt reports Q3 adjusted EPS $2.05, consensus $1.82
Reports Q3 revenue $965.1M, consensus $985.3M.
August 3, 2015
10:12 EDTDEPODepomed to file complaint against Horizon seeking injunction
Subscribe for More Information
07:24 EDTDEPOHorizon Pharma asks Depomed holders to consider bylaw amendments
Subscribe for More Information
July 30, 2015
10:00 EDTDEPOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Altria Group (MO) downgraded to Outperform from Buy at CLSA... Baxter (BAX) downgraded to Market Perform from Outperform at Leerink... Changyou.com (CYOU) downgraded to Hold from Buy at Summit Research... Depomed (DEPO) downgraded to Neutral from Buy at Janney Capital... Euronet (EEFT) downgraded to Neutral from Buy at Monness Crespi... Foundation Medicine (FMI) downgraded to Market Perform at JMP Securities... Garmin (GRMN) downgraded to Underweight from Neutral at JPMorgan... Golden Star Resources (GSS) downgraded to Hold at Canaccord... Grainger (GWW) downgraded on negative catalysts at RBC Capital... Henry Schein (HSIC) downgraded to Hold from Buy at Evercore ISI... LINN Energy (LINE) downgraded to Market Perform from Outperform at Raymond James... LifeLock (LOCK) downgraded to Neutral from Buy at BofA/Merrill... LinnCo (LNCO) downgraded to Market Perform from Outperform at Raymond James... Manitowoc (MTW) downgraded to Hold from Buy at BB&T... PACCAR (PCAR) downgraded to Equal Weight on peak cycle concerns at Morgan Stanley... PG&E (PCG) downgraded to Neutral from Outperform at Credit Suisse... Pacer (PACR) downgraded to Equal Weight from Overweight at Morgan Stanley... Penn Virginia (PVA) downgraded to Sector Perform from Outperform at Scotia... Shutterfly (SFLY) downgraded to Market Perform at Raymond James... Terex (TEX) downgraded to Hold from Buy at BB&T... Total System (TSS) downgraded to Neutral at Baird... Whiting Petroleum (WLL) downgraded to Equal Weight from Overweight at Stephens... Whole Foods (WFM) downgraded to Equal Weight from Overweight at Morgan Stanley.
09:19 EDTDEPODepomed downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
06:32 EDTDEPODepomed downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
July 29, 2015
16:18 EDTDEPODepomed raises FY15 product sales view to $320M-$340M
Prior product sales guidance $310M-$335M. FY15 revenue consensus $327.33M. Raises FY15 adjusted earnings view to $40M-$50M from $16M-$28M. CEO Jim Schoeneck said, "Growth in the second quarter was led by our flagship product NUCYNTA, which had a strong performance in the first quarter of the company distributing the product. We believe that NUCYNTA has blockbuster potential an even bigger opportunity than we originally anticipated and we've just relaunched NUCYNTA with our new product positioning and expanded commercial efforts that we initiated in mid-June. We also see future growth opportunity for Gralise, Cambia and Lazanda including increases in unit demand and market share plus product line extensions. Depomed is now in a period of accelerated growth, one that we see extending well into the future."
16:16 EDTDEPODepomed reports Q2 adjusted EPS 27c, consensus 0c
Subscribe for More Information
16:07 EDTDEPODepomed board rejects acquisition proposal from Horizon Pharma
Subscribe for More Information
16:05 EDTDEPODepomed board rejects takeover proposal from Horizon Pharma
Subscribe for More Information
06:14 EDTMNKBellerophon expands license agreement with Mallinckrodt for INOpule development
Bellerophon (BLPH) has expanded its license agreement with INO Therapeutics, a division of Mallinckrodt (MNK), allowing Bellerophon to develop INOpulse for the treatment of three additional cardiopulmonary diseases, including chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness. Bellerophon's existing license with INO Therapeutics covers the development of INOpulse for pulmonary arterial hypertension, pulmonary hypertension associated with COPD and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Terms of the expanded license agreement include a 5% royalty on net sales for the three additional indications.
July 27, 2015
17:58 EDTMNKMallinckrodt to sell CMDS business to Guerbet for $270M
Subscribe for More Information
July 24, 2015
11:09 EDTDEPOWallachBeth does not see Horizon facing competing suitor for Depomed
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use